Stem Cell Mobilization by G-CSF in Solid and Hematological Malignancies: Single Daily Dose Is Better Than Split Dose in Obese Patients
Journal of Clinical Apheresis, cilt.18, sa.3, ss.120-124, 2003 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 3
- Basım Tarihi: 2003
- Doi Numarası: 10.1002/jca.10068
- Dergi Adı: Journal of Clinical Apheresis
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.120-124
- Anahtar Kelimeler: peripheral blood progenitor cell mobilization, autologous stem cell transplantation, granulocyte colony-stimulating factor, leukapheresis, body mass index, body weight
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
In the past, variable results were reported for single daily and two divided daily doses of granulocyte colony-stimulating factor (G-CSF) in stem cell collection where no study exists investigating the effect of body mass index (BMI) on mobilization. The numbers of CD34+ cells collected were compared in 86 patients with solid or hematological malignancies receiving either single daily (14 μg/kg/day) G-CSF (filgrastim) as group I (n = 36) or two divided doses of G-CSF daily (2 x 7 μg/kg/day) as group II (n = 50). Both groups were divided into subgroups according to their BMI as group a (BMI ≤25 kg/m2) and group b (BMI >25 kg/m2). Two groups were similar in terms of BMI, gender, and disease characteristics. All patients have received G-CSF as a single or two divided doses subcutaneously and aphereses have been done on the 5th day. No significant difference in numbers of CD34+ cells between groups Ia and Ib, groups IIa and IIb, and groups Ia and IIa was found. On the other hand, the mean ratio and the number of CD34+ cells in group Ib were significantly higher than those of group IIb (0.58 ± 0.06% vs. 0.37 ± 0.26%, P = 0.01 and 3.67 ± 0.65 × 104/ kg/ml vs. 1.92 ± 0.37 × 104/kg/ml, P = 0.02). In conclusion, in patients with BMI >25 kg/m2, once daily G-CSF compared to split dose administration induces a greater number of CD34+ stem cell mobilization, which suggests the presence of a different pharmacokinetics in obese patients. © 2003 Wiley-Liss, Inc.